New drug shows promise for Tough-to-Treat multiple myeloma
NCT ID NCT06711705
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called elranatamab in 33 people with multiple myeloma that has returned or not responded after 1 to 3 prior treatments. The goal is to see if the drug can make cancer cells undetectable in tests. Participants will receive elranatamab alone, and the study will monitor how well it works and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of California San Diego
RECRUITINGLa Jolla, California, 92037, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact